Amylyx Pharmaceuticals reported positive top-line results from its Phase 3 Lucidity trial of avexitide, a GLP-1 receptor antagonist, in post-bariatric hypoglycemia (PBH). The study enrolled patients after gastric bypass and showed a 55% reduction in the rate of serious hypoglycemic events versus placebo, beating the pre-specified 35% improvement target. The readout puts Amylyx on track for an FDA filing aimed at the potential first approved therapy for PBH, a rare but high-risk endocrine complication after bariatric surgery. Amylyx has also framed the trial effect as clinically meaningful because serious events can involve loss of consciousness or seizures. In parallel coverage, additional context around the drug’s development and market implications has intensified expectations that clinicians may adopt avexitide quickly if the FDA confirms safety and efficacy. Amylyx’s GLP-1 bet follows years of ALS research turbulence as the company rebuilt its pipeline.